Drug Trial Radar · NCT00645671
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
Last checked: Nov 19, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Mar 2008
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Mar 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
Conditions
- Ocular Inflammation
Interventions
0.5% Loteprednol Etabonate Ophthalmic OintmentDrug
1/2 inch ribbon four times a day for 14 days
Vehicle of Loteprednol Etabonate Ophthalmic OintmentDrug
1/2 inch ribbon four times a day for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.Time frame: Postoperative Day 8 (Visit 5)
- Grade 0 for PainTime frame: Postoperative Day 8 (Visit 5)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
John Hunkeler, MD
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.